Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRDs) and matched unrelated donors (MUDs) on outcome in high-risk patients with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. Patients and Methods: Between 1998 and 2004, 844 patients (median age, 48 years; range, 16 to 62 years) with AML were enrolled onto protocol AMLHD98A that included a risk-adapted treatment strategy. High risk was defined by the presence of unfavorable cytogenetics and/or by no response to induction therapy. Results: Two hundred sixty-seven (32%) of 844 patients were assigned to the high-risk group. Of these 267 patients, 51 patients (19%) achieved complete remission but had adverse cytogenetics, and 216 patients (81%) had no response to induction therapy. Allogeneic HSCT was actually performed in 162 (61%) of 267 high-risk patients, after a median time of 147 days after diagnosis. Graft sources were as follows: MRD (n = 62), MUD (n = 89), haploidentical donor (n = 10), and cord blood (n = 1). The 5-year overall survival rates were 6.5% (95% CI, 3.1% to 13.6%) for patients (n = 105) not proceeding to HSCT and 25.1% (95% CI, 19.1% to 33.0%; from date of transplantation) for patients (n = 162) receiving HSCT. Multivariable analysis including allogeneic HSCT as a time-dependent covariable revealed that allogeneic HSCT significantly improved outcome; there was no difference in outcome between allogeneic HSCT from MRD and MUD. Conclusion: Allogeneic HSCT in younger adults with high-risk AML has a significant beneficial impact on outcome, and allogeneic HSCT from MRD and MUD yields similar results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Cited by
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
“number alterations (18), clinical variables (11), demographic characteristics (2), treatment (3), nuisance (4; nuisance variables are other or missing variables, such as the trial a patient was enrolled in, the year a patient entered the clinical trial, and whether cytogenetic data were missing), and gene–gene interac…”
BackgroundSelf-citationRücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 683
Self-citationKayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Self-citationWang, Y., Liu, Q.-F., Xu, L.-P., Liu, K.-Y., Zhang, X.-H., Ma, X., Fan, Z.-P., Wu, D.-P., & Huang, X.-J. (2015) · Blood · doi:10.1182/blood-2015-02-627786 · Cited by 486
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A. S., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 456
Self-citationSchlenk, R. F., Kayser, S., Bullinger, L., Kobbe, G., Casper, J., Ringhoffer, M., Held, G., Brossart, P., Lübbert, M., Salih, H. R., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578070 · Cited by 404
Self-citationCornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
Self-citationKrönke, J., Schlenk, R. F., Jensen, K.-O., Tschürtz, F., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0371 · Cited by 399
Self-citationTaskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307280 · Cited by 384
Self-citationHematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
How I treat refractory and early relapsed acute myeloid leukemia
Thol, F., Schlenk, R. F., Heuser, M., & Ganser, A. (2015) · Blood · doi:10.1182/blood-2014-10-551911 · Cited by 303
Self-citationGratwohl, A. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.110 · Cited by 293
Schlenk, R. F., Weber, D., Fiedler, W., Salih, H. R., Wulf, G., Salwender, H., Schroeder, T., Kindler, T., Lübbert, M., Wolf, D., et al. (2019) · Blood · doi:10.1182/blood-2018-08-869453 · Cited by 290
Self-citationGaidzik, V. I., Teleanu, V, Papaemmanuil, E., Weber, D., Paschka, P., Hahn, J., Wallrabenstein, T., Kolbinger, B., Köhne, C. H., Horst, H. A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.126 · Cited by 279
Self-citationPrecision oncology for acute myeloid leukemia using a knowledge bank approach
Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V. I., Paschka, P., Heuser, M., Thol, F., Bolli, N., Ganly, P., et al. (2017) · Nature Genetics · doi:10.1038/ng.3756 · Cited by 276
Self-citationSaber, W., Opie, S., Rizzo, J. D., Zhang, M.-J., Horowitz, M. M., & Schriber, J. (2012) · Blood · doi:10.1182/blood-2011-09-381699 · Cited by 250
Gaidzik, V. I., Paschka, P., Späth, D., Habdank, M., Köhne, C.-H., Germing, U., von Lilienfeld-Toal, M., Held, G., Horst, H.-A., Haase, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2886 · Cited by 185
Self-citationGupta, V., Tallman, M. S., & Weisdorf, D. J. (2011) · Blood · doi:10.1182/blood-2010-10-265603 · Cited by 178
Gaidzik, V. I., Schlenk, R. F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H. G., Kremers, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461624 · Cited by 177
“enrolled on the prospective AMLSG multicenter treatment trials AML HD98A (692 of 870 patients [80%]; NCT00146120) and AMLSG 07-04 (1078 of 1112 patients [97%]; NCT00151242; data supplement).(22,23) All patients gave informed consent for both treatment and genetic analysis according to the Declaration of Helsinki.”
MethodSelf-citation
Metadata
- Authors
- Schlenk, R. F., Döhner, K., Mack, S., Stoppel, M., Király, F., Götze, K., Hartmann, F., Horst, H. A., Koller, E., Petzer, A., Grimminger, W., Kobbe, G., Glasmacher, A., Salwender, H., Kirchen, H., Haase, D., Kremers, S., Matzdorff, A., Benner, A., & Döhner, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-10-20
- Volume
- 28
- Issue
- 30
- Pages
- 4642-4648
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141034604
- Cited by
- 228
- References
- 1
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.